(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 0.74% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.75%.
Viatris's revenue in 2025 is $14,115,700,000.On average, 3 Wall Street analysts forecast VTRS's revenue for 2025 to be $16,308,319,577,479, with the lowest VTRS revenue forecast at $16,205,622,565,300, and the highest VTRS revenue forecast at $16,482,820,322,216. On average, 3 Wall Street analysts forecast VTRS's revenue for 2026 to be $16,576,894,544,143, with the lowest VTRS revenue forecast at $16,493,476,393,456, and the highest VTRS revenue forecast at $16,738,601,008,158.
In 2027, VTRS is forecast to generate $16,819,209,407,019 in revenue, with the lowest revenue forecast at $16,714,409,161,523 and the highest revenue forecast at $16,924,009,652,515.